Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
Concentration of Itraconazole Solution in Nasal Secretions
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 6
- Registration Number
- NCT00588016
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 596
- Registration Number
- NCT00585195
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 35
- Registration Number
- NCT00528190
- Locations
- 🇨🇦
Shawn Aaron, The Ottawa Hospital-General Campus, Ottawa, Ontario, Canada
🇨🇦Felix Ratjen, The Hospital for Sick Children, Toronto, Ontario, Canada
Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
- Conditions
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2008-11-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT00336531
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
- Conditions
- Interventions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 489
- Registration Number
- NCT00289991
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
- Conditions
- First Posted Date
- 2004-03-31
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 578
- Registration Number
- NCT00003883
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00079222
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 100
- Registration Number
- NCT00001280
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)
- Conditions
- Interventions
- First Posted Date
- 2002-09-18
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 144
- Registration Number
- NCT00045942
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 400
- Registration Number
- NCT00000639
- Locations
- 🇺🇸
Ucsf Aids Crs, San Francisco, California, United States
🇺🇸USC CRS, Los Angeles, California, United States
🇺🇸Northwestern University CRS, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.